Is the price of ivonib reimbursed by medical insurance? How much does the patient pay out of pocket?

The original drug Ivosidenib (Ivosidenib) has been launched in China, but it is not covered by medical insurance, so patients can only purchase the drug at their own expense. It is understood that the original drug of ivonib is very expensive, which may increase the burden on families with drug needs and heavy financial burdens.

The U.S. Food and Drug Administration (FDA) approved the mutant IDH1 enzyme inhibitor Ivonib for patients with relapsed or refractory IDH1 mutant acute myeloid leukemia (AML) in 2018, and for the first-line treatment of patients aged 75 or older newly diagnosed in 2019 or patients who are not eligible for intensive chemotherapy. Mutation of the IDH1 gene can lead to the accumulation of the tumor metabolite 2-hydroxyglutarate (2-HG). Increased levels of 2-HG interfere with the process by which immature embryonic cells become mature cells. Ivonib reduces the abnormal production of 2-HG by inhibiting isocitrate dehydrogenase 1 (IDH1) . Ivonib is the first approved drug in the IDH1 inhibitor class.

The domestically sold Ivoniboriginal drug, specification0.25g*60 tablets, costs up to RMB 100,000 per box, while the U.S. original version sold overseas costs over RMB 200,000 per box (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.